Monica Ter-Minassian

Monica Ter-Minassian

Auto-generated profile, based on publicly available information

Monica Ter-Minassian

Environmental and Occupational Medicine and Epidemiology Program, Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1996 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JHJ.L. Haines
J.L. Haines
MTM. Ter-Minassian
M. Ter-Minassian
ABA. Bazyk
A. Bazyk
JGJ.F. Gusella
J.F. Gusella
DKD.J. Kim
D.J. Kim
JOJ.R. Oksenberg
J.R. Oksenberg

6 July 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MLMaria Teresa Landi
Maria Teresa Landi
PKPeter A. Kanetsky
Peter A. Kanetsky
STShirley Tsang
Shirley Tsang
BGBert Gold
Bert Gold
DMDavid Munroe
David Munroe
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
Background: Melanoma risk factors include fair pigmentation, multiple nevi, low DNA repair capacity, and CDKN2A or CDK4 mutations. Variants of the melanocortin-1 receptor (MC1R) gene have been associated with fair pigmentation and melanoma risk, and a polymorphism of the Agouti Signaling Protein (ASIP) gene has been associated with dark pigmentation. We examined MC1R and ASIP genotypes in relation to phenotypic characteristics, sporadic and familial melanoma risk, and melanoma thickness as an indicator of disease progression in a Mediterranean population. Methods: We studied 267 melanoma patients and 382 control subjects from a case–control study and a family study in northeastern Italy. Host factors were assessed by physical examination, questionnaire, spectrophotometer, and minimal erythema dose measurement. MC1R was sequenced, ASIP was genotyped, and DNA repair capacity was measured by the host–cell reactivation assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by logistic regression models. Effect modification of the association between MC1R and melanoma risk by phenotypic characteristics and DNA repair capacity was also assessed. All statistical tests were two-sided. Results: Carrying MC1R variant alleles was associated with a two- to fourfold increase in risk of both sporadic and familial melanoma compared with carrying wild-type MC1R, particularly in individuals carrying multiple variant alleles (OR = 3.9; 95% CI = 3.3 to 4.6). This association was stronger in individuals with fewer additional risk factors (those with dark skin or few nevi). MC1R variant allele carriers were also three to four times more likely than were non-carriers to have thick melanomas. The ASIP polymorphism was not associated with pigmentation, nevi, or melanoma risk. Conclusions: MC1R was associated with melanoma risk and progression in a Mediterranean population, particularly in the absence of other strong risk factors, such as freckling or many nevi.

14 January 2013 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
MTMonica Ter-Minassian
Monica Ter-Minassian
JCJennifer A Chan
Jennifer A Chan
SHSusanne M Hooshmand
Susanne M Hooshmand
LBLauren K Brais
Lauren K Brais
ADAnastassia Daskalova
Anastassia Daskalova
MKMatthew H Kulke
Matthew H Kulke
The rarity of neuroendocrine tumors (NET) has contributed to a paucity of large epidemiologic studies of patients with this condition. We characterized presenting symptoms and clinical outcomes in a prospective database of over 900 patients with NET. We used data from patient questionnaires and the medical record to characterize presenting symptoms, disease-free survival (DFS), and overall survival (OS). The majority of patients in this database had gastroenteropancreatic NET. The median duration of patient-reported symptoms before diagnosis was 3.4 months; 19.5% reported durations from 1 to 5 years, 2.5% from 5 to 10 years, and 2% >10 years. The median DFS among patients with resected small bowel NET or pancreatic NET (panNET) was 5.8 and 4.1 years respectively. After correcting for left truncation bias, the median OS was 7.9 years for advanced small bowel NET and 3.9 years for advanced panNET. Chromogranin A (CGA) above twice the upper limit of normal was associated with shorter survival times (hazard ratios 2.8 (1.9, 4.0) P<0.001) in patients with metastatic disease, regardless of tumor subtype. Our data suggest that while most NET patients are diagnosed soon after symptom onset, prolonged symptom duration before diagnosis is a prominent feature of this disease. Though limited to observations from a large referral center, our observations confirm the prognostic value of CGA and suggest that median survival durations may be shorter than that reported in other institutional databases.

1 November 2016 in Pancreas
Verified
Journal Article
Closed access
ZQZhi Rong Qian
Zhi Rong Qian
TLTingting Li
Tingting Li
MTMonica ScD Ter-Minassian
Monica ScD Ter-Minassian
JYJuhong Yang
Juhong Yang
JCJennifer A. Chan
Jennifer A. Chan
MKMatthew H. Md Kulke
Matthew H. Md Kulke
Objective Somatostatin receptors (SSTRs), products of gene superfamily SSTR1-5, are commonly expressed in neuroendocrine tumors (NETs). Somatostatin analogs (SSAs) bind to SSTRs and are used as therapeutic agents in patients with advanced NETs. We hypothesized that tumor SSTR expression status would be associated with clinical outcomes in NET. Methods Expression of the 5 SSTRs was evaluated by immunohistochemistry, using tissue microarrays comprising 173 primary NETs, 24 matched metastases, and 22 metastatic NETs from 195 patients. Cox proportional hazards regression analysis was used to assess the association of SSTR expression status (high vs low) with clinical outcomes, adjusting for potential confounders. Results High expression of SSTR2 was associated with longer overall survival (OS) in the cohort overall (multivariate hazard ratio, 0.42; 95% confidence interval, 0.21–0.84; P = 0.013). In a subgroup of patients with metastatic small intestine NET treated with SSAs and evaluable for progression, SSTR2 expression was associated with both longer progression-free survival (PFS) and OS. No associations with PFS or OS were observed with expression of other SSTRs. Conclusions Our study demonstrated that expression of SSTR2, but not other SSTRs, is associated with longer OS. In patients treated with SSAs, expression of SSTR2 is associated with longer PFS survival.

20 September 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ZQZhi Rong Qian
Zhi Rong Qian
MTMonica Ter-Minassian
Monica Ter-Minassian
JCJennifer A. Chan
Jennifer A. Chan
YIYu Imamura
Yu Imamura
SHSusanne M. Hooshmand
Susanne M. Hooshmand
MKMatthew H. Kulke
Matthew H. Kulke
Purpose: Clinical studies have implicated the mechanistic target of rapamycin (serine/threonine kinase; MTOR) pathway in the regulation of neuroendocrine tumor (NET) growth. We explored whether expression of MTOR pathway components has prognostic significance in NET patients. Patients and Methods: We evaluated immunohistochemical expression of MTOR and phospho (p) –MTOR; its downstream targets RPS6KB1, RPS6, and EIF4EBP1; and its upstream regulators, in a cohort of 195 archival neuroendocrine tumors. We correlated expression levels with clinical outcomes, after adjusting for other prognostic variables. Results: We observed anticipated correlations between expression of upstream components of the MTOR pathway and their downstream targets. Expression of PIK3CA, MTOR, or p-EIF4EBP1 was associated with high MKI67 (Ki-67) labeling index. We failed to identify clinical correlations associated with expression of the upstream regulators TSC1, TSC2, AKT, p-AKT, PDPK1, PTEN, PIK3R1, or PIK3CA. In contrast, high expression of MTOR or its activated downstream targets p-RPS6KB1, p-RPS6, or p-EIF4EBP1 was associated with adverse clinical outcomes. Conclusion: Our observations suggest that expression of MTOR or its downstream targets may be adverse prognostic factors in neuroendocrine tumors.

1 October 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MMMary McMaster
Mary McMaster
LGLynn R. Goldin
Lynn R. Goldin
YBYan Bai
Yan Bai
MTMonica Ter-Minassian
Monica Ter-Minassian
SBStefan Boehringer
Stefan Boehringer
MTMargaret A. Tucker
Margaret A. Tucker